BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17715118)

  • 1. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.
    Poletti PA; Saudan P; Platon A; Mermillod B; Sautter AM; Vermeulen B; Sarasin FP; Becker CD; Martin PY
    AJR Am J Roentgenol; 2007 Sep; 189(3):687-92. PubMed ID: 17715118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine.
    Merkle M; Sauter M; Argirov M; Wörnle M
    Ren Fail; 2010 Jan; 32(1):85-90. PubMed ID: 20113272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does intravenous or oral high-dose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C?
    Erturk M; Uslu N; Gorgulu S; Akbay E; Kurtulus G; Akturk IF; Akgul O; Surgit O; Uzun F; Gul M; Isiksacan N; Yildirim A
    Coron Artery Dis; 2014 Mar; 25(2):111-7. PubMed ID: 24365793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
    Chousterman BG; Bouadma L; Moutereau S; Loric S; Alvarez-Gonzalez A; Mekontso-Dessap A; Laissy JP; Rahmouni A; Katsahian S; Brochard L; Schortgen F
    J Crit Care; 2013 Oct; 28(5):701-9. PubMed ID: 23683568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 20-Hour preprocedural hydration is not superior to 5-hour preprocedural hydration in the prevention of contrast-induced increases in serum creatinine and cystatin C.
    Torigoe K; Tamura A; Watanabe T; Kadota J
    Int J Cardiol; 2013 Sep; 167(5):2200-3. PubMed ID: 22717305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Acetylcysteine does not artifactually lower plasma creatinine concentration.
    Haase M; Haase-Fielitz A; Ratnaike S; Reade MC; Bagshaw SM; Morgera S; Dragun D; Bellomo R
    Nephrol Dial Transplant; 2008 May; 23(5):1581-7. PubMed ID: 18202091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Of hypes and hopes: N-acetylcysteine and cystatin C.
    Schultz MJ; Royakkers AA; Bouman CS
    AJR Am J Roentgenol; 2008 Mar; 190(3):W224; author reply W225. PubMed ID: 18287418
    [No Abstract]   [Full Text] [Related]  

  • 10. N-acetylcysteine does not prevent contrast nephropathy in patients with renal impairment undergoing emergency CT: a randomized study.
    Poletti PA; Platon A; De Seigneux S; Dupuis-Lozeron E; Sarasin F; Becker CD; Perneger T; Saudan P; Martin PY
    BMC Nephrol; 2013 Jun; 14():119. PubMed ID: 23731573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of N-acetylcysteine on renal function in patients with chronic kidney disease.
    Mainra R; Gallo K; Moist L
    Nephrology (Carlton); 2007 Oct; 12(5):510-3. PubMed ID: 17803476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery.
    Ristikankare A; Kuitunen T; Kuitunen A; Uotila L; Vento A; Suojaranta-Ylinen R; Salmenperä M; Pöyhiä R
    Br J Anaesth; 2006 Nov; 97(5):611-6. PubMed ID: 16914459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial.
    Moist L; Sontrop JM; Gallo K; Mainra R; Cutler M; Freeman D; House AA
    Am J Kidney Dis; 2010 Oct; 56(4):643-50. PubMed ID: 20541301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C.
    Alioglu E; Saygi S; Turk U; Kirilmaz B; Tuzun N; Duman C; Tengiz I; Yildiz S; Ercan E
    Cardiovasc Ther; 2013 Jun; 31(3):168-73. PubMed ID: 22212518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes.
    Oddoze C; Morange S; Portugal H; Berland Y; Dussol B
    Am J Kidney Dis; 2001 Aug; 38(2):310-6. PubMed ID: 11479157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
    Briguori C; Visconti G; Focaccio A; Airoldi F; Valgimigli M; Sangiorgi GM; Golia B; Ricciardelli B; Condorelli G;
    Circulation; 2011 Sep; 124(11):1260-9. PubMed ID: 21844075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
    Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
    J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
    Briguori C; Colombo A; Airoldi F; Morici N; Sangiorgi GM; Violante A; Focaccio A; Montorfano M; Carlino M; Condorelli G; Ricciardelli B
    Kidney Int; 2005 Nov; 68(5):2250-5. PubMed ID: 16221226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.